Immunogenicity of xenopeptide hormone therapies

Peptides

Volumn 27, Issue 7, 2006, Pages 1902-1910

  Schnabel, Catherine A ^a   Fineberg, S Edwin ^b   Kim, Dennis D ^a  

^a AMYLIN PHARMACEUTICALS INC   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hormone therapies; Immunogenicity; Xenopeptide

Indexed keywords

ANTIBODY; BOVINE INSULIN; C PEPTIDE; CALCITONIN; CALCIUM; DRUG ANTIBODY; ELCATONIN; EXENDIN 4; GLUCAGON; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN; INSULIN ANTIBODY; MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; PANCREAS POLYPEPTIDE; PEPTIDE DERIVATIVE; PIG INSULIN; PROINSULIN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT HUMAN INSULIN; SALCATONIN; SYNTHETIC INSULIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANALGESIC ACTIVITY; ANAPHYLAXIS; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN ANTIBODY COMPLEX; AUTOIMMUNE DISEASE; BLOOD TRANSFUSION; BONE DISEASE; CALCIUM BLOOD LEVEL; CHRONIC DISEASE; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG POTENCY; DRUG PURITY; DRUG REEXPOSURE; ELECTROLYTE DISTURBANCE; ENDOCRINE DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE APLASIA; GLUCAGON RELEASE; HORMONAL THERAPY; HUMAN; HYPOGLYCEMIA; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOTOXICITY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN TREATMENT; LUPUS LIKE SYNDROME; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOGENESIS IMPERFECTA; PAGET BONE DISEASE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PURE RED CELL ANEMIA; RADIOIMMUNOASSAY; REVIEW; SINGLE DRUG DOSE; SKIN MANIFESTATION; SURFACE PLASMON RESONANCE; SYSTEMIC DISEASE; T LYMPHOCYTE ACTIVATION; THROMBOCYTOPENIA; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIBODY FORMATION; ANTIBODY SPECIFICITY; GENETIC ENGINEERING; HUMANS; IMMUNE SYSTEM; IMMUNOTHERAPY; INSULIN; PEPTIDE HORMONES; PEPTIDES; RECOMBINANT PROTEINS;

ANIMALIA;

EID: 33744997617     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2006.01.019     Document Type: Review

References (107)

1. Amylin Pharmaceuticals Inc. Data on file.
2. Arias P., Kerner W., Navascues I., Schafauer G., and Pfieffer E.F. Semisynthetic human insulin and purified pork insulin do not differ in their biological potency. Klin Wochenschr 24 (1984) 1145-1150
3. Bang N.U. Leeches, snakes, ticks, and vampire bats in today's cardiovascular drug development. Circulation 84 (1991) 436-438
4. Bennett C.L., Luminari S., Nissenson A.R., Tallman M.S., Klinge S.A., Mc Williams N., et al. Pure red cell aplasia and epoetin therapy. N Engl J Med 35 (2004) 1403-1408
5. Benucci M., Li Gobbi F., Fossi F., Manfredi M., and Del Rosso A. J Clin Rheumatol 1 (2005) 47-49
6. Berson S.A., Yalow R.S., Bauman A., Rothschild M.A., and Newerly K. Insulin-I-131 metabolism in human subjects: demonstration of insulin binding globulin in the circulation of insulin treated subjects. J Clin Invest 35 (1956) 170
7. Bertolotto A. Neutralizing antibodies to interferon beta: implications for the management of multiple sclerosis. Curr Opin Neurol 17 (2004) 241-246
8. Betterle C., Fabris P., Zanchetta R., Pedini B., Tositti G., Bosi E., et al. Autoimmunity against pancreatic islets and other tissues before and after interferon-alpha therapy in patients with hepatitis C virus chronic infection. Diabetes Care 23 (2000) 1177-1181
9. Bhavsar S, Watkins J, Young A. Comparison of central and peripheral effects of exendin-4 and GLP-1 on food intake in rats. Program and Abstracts: 80th Annual Meeting of the Endocrine Society, 1988 [abstract P3-223].
10. Bijvoet O.L.M., van der Sluys J., and Jansen A.P. Effects of calcitonin on patients with Paget's disease, thyrotoxicosism or hypercalcemia. Lancet 1 (1968) 876
11. Bloom S.R., Barnes A.J., Adrian T.E., and Polak J.M. Autoimmunity in diabetics induced by hormonal contaminants of insulin. Lancet 1 (1979) 14-17
12. Bosi E., Minelli R., Bazzigaluppi E., and Salvi M. Fulminant autoimmune type 1 diabetes during interferon-alpha therapy: a case of Th1-mediated disease?. Diabetic Med 18 (2001) 329-332
13. Buse J.B., Henry R.R., Han J., Kim D.D., Fineman M.S., Alain D., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27 (2004) 2628-2635
14. ® (exenatide) injection, Prescribing information. www.byetta.com. Byetta is a registered trademark of Amylin Pharmaceuticals Inc.
15. Casadevall N., Nataf J., Viron B., Kolta A., Kiladjian J.J., Martin-Dupont P., et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 34 (2002) 469-475
16. Chamberlain P., and Mire-Sluis A.R. An overview of scientific and regulatory issues for the imunogenicity of biological products. Dev Biol 112 (2003) 3-11
17. Chance R.E., Root M.A., and Galloway J.A. The immunogenicity of insulin preparations. Acta Endocrinol Suppl (Copenh) 205 (1976) 185-198
18. Chen Y.E., and Drucker D. Tissue-specific expression of unique mRNAs that encode pro-glucagon-derived peptides or exendin-4 in the lizard. J Biol Chem 272 (1997) 4108-4115
19. Chirino A.J., Ary M.L., and Marshall S.A. Minimizing the immunogenicity of protein therapeutics. Drug Disc Today 9 (2004) 282-290
20. Chirino A.J., and Mire-Sluis A. Characterizing biological products and assessing comparability following manufacturing changes. Nat Biotech 11 (2004) 1383-1390
21. D'Alessio D.A., Vogel R., Prigeon R., Laschansky E., Koerker D., Eng J., et al. Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons. J Clin Invest 97 (1996) 133-138
22. Deckert T. The immunogenicity of new insulins. Diabetes 34 Suppl. 2 (1985) 94-96
23. DeFronzo R.A., Ratner R.E., Han J., Kim D.D., Fineman M.S., and Baron A.D. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28 (2005) 1092-1100
24. Degn K.B., Brock B., Juhl C.B., Djurhuus C.B., Grubert J., Kim D., et al. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes 53 (2004) 2397-2403
25. Deitrich F.M., Fischer J.A., and Bijvoet O.L.M. Formation of antibodies to synthetic human calcitonin during treatment of Paget's disease. Acta Endocrin 92 (1979) 468-476
26. DeRose J., Singer F.R., Avramides A., Flores A., Dziadiw R., Baker R.K., et al. Response of Paget's disease to porcine and salmon calcitonins. Am J Med 56 (1974) 858-866
27. DeWitt D.E., and Hirsch I.B. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: a scientific review. JAMA 289 (2003) 2254-2264
28. Edward C.M., Stanley S.A., Davis R., Brynes A.E., Frost G.S., Seal L.J., et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 281 (2001) E155-E161
29. Egan J.M., Clocquet A.R., and Elahi D. The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab 87 (2002) 1282-1290
30. Eng J., Kleinman W.A., Singh L., et al. Isolation and characterization of exendin-4, an exendin-3 analogue from Heloderma suspectum venom. J Biol Chem 267 (1992) 7402-7405
31. Fineberg S.E., Galloway J.A., Fineberg N.S., and Goldman J. Effects of species of origin, purification levels, and formulation on insulin immunogenicity. Diabetes 32 (1983) 592-599
32. Fineberg S.E., Galloway J.A., Fineberg N.S., Rathbun M.J., and Hufferd S. Immunogenicity of recombinant DNA human insulin. Diabetologia 25 (1983) 465-469
33. Fineberg S.E. Insulin allergy and insulin resistance. In: Lebovitz H.E. (Ed). Therapy for diabetes mellitus and related disorders (1994), American Diabetes Association, Alexandria, Virginia 178-184
34. Fireman P., Fineberg S.E., and Galloway J.A. Development of IgE antibodies to human (recombinant DNA) porcine, and bovine insulins in diabetic subjects. Diabetes Care 5 Suppl. 2 (1982) 119-125
35. Fleischer N., Abe K., Liddle G.W., Orth D.N., and Nicholson W.E. ACTH antibodies in patients receiving depot porcine ACTH to hasten recovery from pituitary-adrenal suppression. J Clin Invest 46 (1967) 196-204
36. Frantz S. 2004 approvals: the demise of the blockbuster?. Nat Rev Drug Discov 4 (2005) 93-94
37. Gardell S.J., Ramjit D.R., Stabilito I.I., Fujita T., Lynch J.J., Cuca G.C., et al. Effective thrombolysis without marked plasminemia after bolus intravenous administration of vampire bat salivary plasminogen activator in rabbits. Circulation 84 (1991) 244-253
38. Grauer A., Reinel H.H., Ziegler R., and Raue F. Neutralizing antibodies against calcitonin. Horm Metab Res 25 (1993) 486-488
39. Grauer A., Reinel H.H., Ljunghall S., Lindh E., Ziegler R., and Raue F. Formation of neutralizing antibodies against human calcitonin in a patients with postmenopausal osteoporosis. Calcif Tissue Int 52 Suppl. 1 (1993) 317
40. Gruchalla R.S. Drug allergy. J Allergy Clin Immunol 111 (2003) S548-S549
41. Hacke W., Albers G., Al-Rawi Y., Bogousslavsky J., and Davalos A. The desmoteplase in acute ischemic stroke trial (DIAS): a phase 2 MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 36 (2005) 66-73
42. Haddad J.G., and Caldwell J.G. Calcitonin resistance: clinical and immunological studies in subjects with Paget's disease of bone treated with porcine and salmon calcitonins. J Clin Invest 51 (1972) 3133-3141
43. Hanley J.P., and Haydon G.H. The biology of interferon-alpha and the clinical significance of anti-interferon antibodies. Leuk Lymphoma 29 (1998) 257-268
44. Heintz G., Waterhouse T., Petrella E., Fischer K., and Hiles R. Validation of an ELISA used to determine anti-exenatide antibody cross-reactivity to GLP-1 and glucagon in human plasma samples. AAPS Pharm Sci. 6 October (2004)
45. Hermeling S., Crommelin D.J.A., Schellekens H., and Jiskoot W. Structure-immunogenicity relationships of therapeutic proteins. Pharma Res 2 (2004) 897-903
46. Home P.D., Shepherd G.A., Noy G., Massi-Benedetti M., Hanning I., Burrin J.M., et al. Comparison of the activity and pharmacokinetics of porcine insulin and human insulin as assessed by the glucose clamp technique in normal and diabetic man. Diabetes Care 6 (1983) 23-28
47. Home P.D., Mann N.P., Hutchison A.S., Park R., Walford S., Murphy M., et al. A fifteen-month double-blind cross-over study of the efficacy and antigenicity of human and pork insulin. Diabet Med 1 (1984) 93-98
48. Howley D.C., Fineberg S.E., Nolen P.A., Stone M., Gibson R.G., Fineberg N.S., et al. The therapeutic efficacy of human insulin (recombinant DNA) in patients with insulin-dependent diabetes mellitus: a comparative study with purified porcine insulin. Diabetes Care 5 (1982) 73-77
49. http://www.iddtindia.org/about.asp; http://www.geocities.com/beefandporkinsulin/Canada_NewsPage 11.html; accessed June 2005.
50. Huwyler R., Born W., Ohnhaus E.E., and Fischer J.A. Plasma kinetics and urinary excretion of exogenous human and salmon calcitonin in man. Am J Physiol 236 (1979) E15-E19
51. Inzerillo A.M., Zaidi M., and Huang C.L.-H. Calcitonin: physiological actions and clinical applications. J Ped Endocrin Metab 17 (2004) 931-940
52. Ishibashi O., Kobayashi M., Maegawa H., Watanabe N., Takata Y., Okuno Y., et al. Can insulin antibodies of diabetic patients distinguish human insulin from porcine insulin?. Horm Metab Res 18 (1986) 470-472
53. Jacquemin M.G., and Saint-Remy J.M. Factor VII immunogenicity. Haemophilia 4 (1998) 552-557
54. Kapurniotu A., and Taylor J.W. Structural and conformational requirements for human calcitonin activity: design, synthesis, and study of lactam-bridged analogues. J Med Chem 38 (1995) 836-847
55. Kendall D.M., Riddle M.C., Rosenstock J., Zhuang D., Kim D.D., Fineman M.S., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28 (2005) 1083-1091
56. Kolterman O.G., Buse J.B., Fineman M.S., Gaines E., Heintz S., Bicsak T.A., et al. Synthetic exendin 4 (AC2993) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 88 (2003) 3082-3089
57. Kolterman O.G., Kim D.D., Shen L., Ruggles J.A., Nielsen L.L., Fineman M.S., et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health-Syst Pharmacy 62 (2005) 173-181
58. Koren E., Zuckerman L.A., and Mire-Sluis A.R. Immune responses to therapeutic proteins in humans-clinical significance, assessment and prediction. Curr Pharm Biotech 3 (2002) 349-360
59. Kromminga A., and Schellekens H. Antibodies against erythropoietin and other protein-based therapeutics. Ann N Y Acad Sci 1050 (2005) 257-265
60. Landon J., and Friedman M. Greenwood Antibodies to corticotrophin and their relation to adrenal function in children receiving corticotrophin therapy. Lancet 1 (1967) 652
61. Levy F., Muff S., Dotti-Sigrist S., Dambacher M.A., and Fischer J.A. Formation of neutralizing antibodies during intranasal synthetic salmon calcitonin treatment of Paget's disease. J Clin Endocrin Metab 67 (1988) 541-545
62. Li J., Yang C., Xia Y., Bertino A., Glaspy J., Roberts M., et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 98 (2001) 3241-3248
63. Lo Cascio V., Adami S., Galvanini G., Lazzaretto R., Ferrari M., Tartarotti D., et al. Response of Paget's disease to human calcitonin in patients resistant to porcine calcitonin. J Endocrinol Invest 7 (1984) 85-88
64. Ludvigsson J. Insulin antibodies in diabetic children treated with monocomponent porcine insulin from the onset: relationship to B-cell function and partial remission. Diabetologia 26 (1984) 138-141
65. Marshall M.O., Heding L.G., Villumsen J., Akerblom H.K., Baevre H., Dahlquist G., et al. Development of insulin antibodies, metabolic control and B-cell function in newly diagnosed insulin dependent diabetic children treated with monocomponent human insulin or monocomponent porcine insulin. Diabetes Res 9 (1988) 169-175
66. Marshall S.A., Lazar G.A., Chirino A.J., and Desjarlais J.R. Rational design and engineering of therapeutic proteins. Drug Disc Tech 8 (2003) 212-221
67. Martin T.J. Treatment of Paget's disease with the calcitonins. Aust N Z J Med 9 (1979) 36-43
68. Melick R.A., Gill J.R., Berson S.A., Yalow R.S., Bartter F.C., Potts J.T., et al. Antibodies and clinical resistance to parathyroid hormone. N Engl J Med 276 (1967) 144
69. Mire-Sluis A., Gaines Das R., and Lernmark A. Standardization of antibody preparations for use in immunogenicity studies: a case study using the World Health Organization International Collaborative Study for Islet Cell Antibodies. Dev Biol (Basel) 112 (2003) 153-163
70. Muff R., Dambacher M.A., and Fischer J.A. Formation of neutralizing antibodies during intranasal synthetic salmon calcitonin treatment of postmenopausal osteoporosis. Osteoporosis Int 1 (1991) 72-75
71. Niall H.D., Keutmann H.T., Copp D.H., and Potts J.T. Amino acid sequence of salmon ultimobranchial calcitonin. Proc Natl Acad Sci 64 (1969) 771
72. Nielsen L.L., Young A.A., and Parkes D. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Reg Pept 117 (2004) 77-88
73. O'Garra A., and Vieira P. Regulatory T cells and mechanisms of immune system control. Nat Med 10 (2004) 01-805
74. Olsen N. Drug-induced Autoimmunity. Best Pract Res Clin Rheumatol 18 (2004) 677-688
75. Parkes D., Jodka C., Smith P., Nayak S., Rinehart L., Gingerich R., et al. Pharmacokinetic actions of exendin-4 in the rat: comparison with glucagon-like peptide 1. Drug Dev Res 53 (2001) 260-267
76. Parkes D.G., Pittner R., Jodka C., Smith P., and Young A. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism 50 (2001) 583-589
77. Poon T, Taylor K, Nielsen L, Boies S, Zhuang D, Varns A, et al., Effects of exenatide (synthetic exendin-4) on glucose control and safety in patients with type 2 diabetes treated with metformin, a sulfonyurea, or both: an ongoing, open-label phase 3 trial. Endocr Pract 10:7 [abstract 20].
78. Potts Jr. J.T., Niall Jr. H.D., Keutmann H.T., Brewer H.B., and Deftos L.J. The amino acid sequence of porcine thyrocalcitonin. Proc Natl Acad Sci 59 (1968) 1321
79. Potts Jr. J.T., Niall H.D., Deftos L.J., and Calcitonin. Curr Top Exp Endocrinol 1 (1971) 151-173
80. Reeves W.G., and Kelly U. Insulin antibodies induced by bovine insulin therapy. Clin Exp Immunol 50 (1982) 163-170
81. Reginster J.Y., Almer S., Gaspar S., Collette J., Deroisy R., and Franchimont P. Evidence that specific antibodies do not reduce salmon calcitonin activity in vivo. Antibody Immunoconj Radiopharm 2 (1989) 117-124
82. Reginster J.Y., Gaspar S., Deroisy R., Zegels B., and Franchimont P. Prevention of osteoporosis with nasal calcitonin: effect of anti-salmon calcitonin antibody formation. Osteopor Int 3 (1993) 261-264
83. Richter B, Neises G. Human versus animal insulin in people with diabetes mellitus. Cochrane Database Sys Review, J Wiley and Sons (ed); 2004. CDO03816.
84. Rojanasathit S., Rosenberg E., and Haddad Jr. J.G. Paget's bone disease: response to human calcitonin in patients resistant to salmon calcitonin. Lancet 2 (1974) 1412-1415
85. Roth J., Glick S.M., Yalow R.S., and Berson S.A. Antibodies to human growth hormone (HGH) in human subjects treated with HGH. J Clin Invest 43 (1964) 1056-1065
86. Roth J., Glick S.M., Klein L.A., and Petersen M.J. Specific antibody to vasopressin in man. J Clin Endocrinol Metab 26 6 (1966) 671-675
87. Sarzi-Puttini P., Atzeni F., Capsoni F., Lubrano E., and Doria A. Drug-induced autoimmunity. Autoimunity 38 (2005) 507-518
88. Schellekens H. Immunogenicity of therapeutic proteins. Nephrol Dial Transplant 28 (2003) 1257-1259
89. Schellekens H. Relationship between biopharmaceutical immunogenicity of epoetin alpha and pure red cell aplasia. Curr Med Res Opin 5 (2003) 433-434
90. Schellekens H., and Casadevall N. Immunogenicity of recombinant human proteins: causes and consequences. J Neurol 251 Suppl. 2 (2004) 11/4-11/9
91. Schellekens H. Bioequivalence and the immunogenicity of Biopharmaceuticals. Nat Rev 1 (2002) 457-462
92. Schellekens H. Immunologic mechanisms of EPO-associated pure red cell aplasia. Best Prac Res Clin Haem 18 (2005) 473-480
93. Schernthaner G. Immunogenicity and allergenic potential of animal and human insulins. Diabetes Care 16 (1993) 155-165
94. Schirra J., Sturm K., Leicht P., Arnold R., and Goke B. Katschinski Exendin (9-39)amide is an antagonist of glucagons-like peptide-1(7-36) amide in humans. J Clin Invest 101 (1998) 1421-1430
95. Singer F.R., Aldred J.P., Neer M., Krane S.M., Potts J.T., and Bloch K.J. An evaluation of antibodies and clinical resistance to salmon calcitonin. J Clin Invest 51 (1972) 2231-2238
96. Singer F.R., Fredericks R.S., and Minkin C. Salmon calcitonin therapy for Paget's disease of bone. The problem of acquired clinical resistance. Arthritis Rheum 23 (1980) 1148-1153
97. Singer F.R. Clinical efficacy of salmon calcitonin in Paget's disease of bone. Calcif Tissue Int 49 (1991) S7-S8
98. Smith L.F. Species variation in the amino acid sequence of insulin. Am J Med 40 (1966) 662-666
99. Steis R.G., Smith II J.W., Urba W.J., Venzon D.J., Longo D.L., Barney R., et al. Loss of interferon antibodies during prolonged continuous interferon-alpha 2a therapy in hairy cell leukemia. Blood 77 (1991) 792-798
100. Szayna M, Doyle ME, Betkey JA, Holloway HW, Spencer RGS, Greig NH, et al., Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinol 200; 141: 1936-1941.
101. Van Haeften T.W. Clinical significance of insulin antibodies in insulin-treated patients. Diabetes Care 9 (1989) 641-648
102. Velcovsky H.G., and Federlin K.F. Insulin-specific IgG and IgE antibody response in type 1 diabetic subjects exclusively treated with human insulin (recombinant DNA). Diabetes Care 5 (1982) 126-128
103. Wadhwa M., Bird C., Dilger P., Gaines-Das R., and Thorpe R. Strategies for detection, measurement and characterization of unwanted antibodies induced by therapeutic biologicals. J Immunol Methods 278 (2003) 1-17
104. Walford S., Allison S.P., and Reeves W.G. The effect of insulin antibodies on insulin dose and diabetic control. Diabetologia 22 (1982) 106-110
105. Woodhouse N.J.Y., Mohamedally S.M., Saed-Nejad F., and Martin T.J. Development and significance of antibodies to salmon calcitonin in patients with Paget's disease on long-term administration. Br Med J 2 (1977) 927-929
106. Young A.A., Gedulin B.R., Bhavsar S., Bodkin N., Jodka C., Hansen B., et al. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 48 (1999) 1026-1034
107. Zaidi M., Moonga B.S., and Abe E. Calcitonin and bone formation: a knockout full of surprises. J Clin Invest 110 (2002) 1769-1771